L 636499

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 559190

CAS#: 71474-64-1

Description: L 636499 is a bioactive chemical.


Chemical Structure

img
L 636499
CAS# 71474-64-1

Theoretical Analysis

MedKoo Cat#: 559190
Name: L 636499
CAS#: 71474-64-1
Chemical Formula: C15H10O4S
Exact Mass: 286.03
Molecular Weight: 286.3
Elemental Analysis: C, 62.93; H, 3.52; O, 22.35; S, 11.20

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L 636499; L-636499; L636499;

IUPAC/Chemical Name: dibenzo[b,f]thiepine-3-carboxylic acid 5,5-dioxide

InChi Key: ASJSKZXRWOAFGL-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H10O4S/c16-15(17)12-8-7-11-6-5-10-3-1-2-4-13(10)20(18,19)14(11)9-12/h1-9H,(H,16,17)

SMILES Code: O=C(C1=CC=C(C=CC2=CC=CC=C23)C(S3(=O)=O)=C1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 286.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Siegfried ME, Bush LR. Dual antagonism by L-636,499 of serotonin and thromboxane A2 induced aggregation of canine platelets. Thromb Res. 1990 Dec 1;60(5):343-53. PubMed PMID: 2084956.

2: Hedlund H, Andersson KE, Fovaeus M, Holmquist F, Uski T. Characterization of contraction-mediating prostanoid receptors in human penile erectile tissues. J Urol. 1989 Jan;141(1):182-6. PubMed PMID: 2521189.

3: Liel N, Mais DE, Halushka PV. Desensitization of platelet thromboxane A2/prostaglandin H2 receptors by the mimetic U46619. J Pharmacol Exp Ther. 1988 Dec;247(3):1133-8. PubMed PMID: 2974487.

4: Fitzgerald DJ, Fragetta J, FitzGerald GA. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest. 1988 Nov;82(5):1708-13. PubMed PMID: 3183064; PubMed Central PMCID: PMC442741.

5: Swayne GT, Maguire J, Dolan J, Raval P, Dane G, Greener M, Owen DA. Evidence for homogeneity of thromboxane A2 receptor using structurally different antagonists. Eur J Pharmacol. 1988 Aug 2;152(3):311-9. PubMed PMID: 2975605.

6: Vargaftig B, Joseph D, Hatmi M. Interference of the thromboxane antagonist SK&F 88046 with platelet activation and subsequent desensitization by arachidonic acid and the thromboxane mimetics U46619 and EP171. Thromb Res. 1987 May 15;46(4):509-17. PubMed PMID: 3039684.

7: Fitzgerald DJ, Fragetta J, Fenelon LC, FitzGerald GA. Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:496-500. PubMed PMID: 2959103.

8: Uski TK, Andersson KE. Effects of the thromboxane-receptor antagonist L-636,499 on feline cerebral arteries. Acta Physiol Scand. 1986 Dec;128(4):605-11. PubMed PMID: 2949488.

9: Fitzgerald DJ, Doran J, Jackson E, FitzGerald GA. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. J Clin Invest. 1986 Feb;77(2):496-502. PubMed PMID: 3003161; PubMed Central PMCID: PMC423371.

10: Foegh ML, Alijani MR, Helfrich GB, Khirabadi BS, Ramwell PW. Prolongation of cardiac allograft survival with the PAF antagonist BN-52021 and the thromboxane receptor antagonists L640035 and L636499. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:381-4. PubMed PMID: 2936126.